KR20230118144A - 치환된 피라졸로 피페리딘 카르복실산 - Google Patents

치환된 피라졸로 피페리딘 카르복실산 Download PDF

Info

Publication number
KR20230118144A
KR20230118144A KR1020237022818A KR20237022818A KR20230118144A KR 20230118144 A KR20230118144 A KR 20230118144A KR 1020237022818 A KR1020237022818 A KR 1020237022818A KR 20237022818 A KR20237022818 A KR 20237022818A KR 20230118144 A KR20230118144 A KR 20230118144A
Authority
KR
South Korea
Prior art keywords
compound
compounds
present
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022818A
Other languages
English (en)
Korean (ko)
Inventor
알렉산드로스 바칼로포울로스
마리-피에르 콜린-크뢰펠린
누리아 오르테가 헤르난데즈
안드레 디스카우
멜리사 보울타다키스-아라피니스
리사 칸디쉬
티모 스텔펠트
일카 마타르
루카스 허드슨 호프마이스터
페터 샌드너
프란크 분더
리사 디츠
로베르트 알란 벱스터
카르스텐 쉬메크
토마스 몬드리츠키
Original Assignee
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 악티엔게젤샤프트 filed Critical 바이엘 악티엔게젤샤프트
Publication of KR20230118144A publication Critical patent/KR20230118144A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237022818A 2020-12-10 2021-12-09 치환된 피라졸로 피페리딘 카르복실산 Pending KR20230118144A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
EP20213020.9 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
KR20230118144A true KR20230118144A (ko) 2023-08-10

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022818A Pending KR20230118144A (ko) 2020-12-10 2021-12-09 치환된 피라졸로 피페리딘 카르복실산

Country Status (31)

Country Link
US (1) US20240051935A1 (https=)
EP (1) EP4259617B1 (https=)
JP (1) JP2023552583A (https=)
KR (1) KR20230118144A (https=)
CN (1) CN116710439A (https=)
AR (1) AR124297A1 (https=)
AU (1) AU2021393988A1 (https=)
CA (1) CA3204495A1 (https=)
CL (1) CL2023001632A1 (https=)
CO (1) CO2023007335A2 (https=)
CR (1) CR20230242A (https=)
DK (1) DK4259617T3 (https=)
DO (1) DOP2023000115A (https=)
EC (1) ECSP23040828A (https=)
ES (1) ES2997117T3 (https=)
FI (1) FI4259617T3 (https=)
GE (2) GEAP202316287A (https=)
HR (1) HRP20241543T1 (https=)
HU (1) HUE069255T2 (https=)
IL (1) IL303296A (https=)
JO (1) JOP20230132A1 (https=)
LT (1) LT4259617T (https=)
MX (1) MX2023006903A (https=)
PE (1) PE20231501A1 (https=)
PL (1) PL4259617T3 (https=)
PT (1) PT4259617T (https=)
RS (1) RS66294B1 (https=)
SA (1) SA523441083B1 (https=)
SI (1) SI4259617T1 (https=)
TW (1) TW202237589A (https=)
WO (1) WO2022122914A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) * 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EA023221B1 (ru) 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2632551B1 (en) * 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
ES2748798T3 (es) * 2012-09-07 2020-03-18 Boehringer Ingelheim Int Alcoxi pirazoles como activadores de la guanilato ciclasa soluble
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
UA121558C2 (uk) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
JP7458683B2 (ja) * 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのsGC活性化剤の使用
CN116829545A (zh) * 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸

Also Published As

Publication number Publication date
GEAP202316287A (en) 2023-09-11
ECSP23040828A (es) 2023-07-31
HUE069255T2 (hu) 2025-02-28
SI4259617T1 (sl) 2025-02-28
PL4259617T3 (pl) 2025-03-17
FI4259617T3 (fi) 2024-11-27
DK4259617T3 (da) 2024-12-09
CN116710439A (zh) 2023-09-05
SA523441083B1 (ar) 2025-06-12
JOP20230132A1 (ar) 2023-06-08
TW202237589A (zh) 2022-10-01
MX2023006903A (es) 2023-06-26
GEP20247649B (en) 2024-07-25
CL2023001632A1 (es) 2023-11-10
AU2021393988A1 (en) 2023-06-22
AU2021393988A9 (en) 2024-09-19
ES2997117T3 (en) 2025-02-14
CO2023007335A2 (es) 2023-06-09
CR20230242A (es) 2023-07-19
PT4259617T (pt) 2024-12-05
PE20231501A1 (es) 2023-09-26
IL303296A (en) 2023-07-01
AR124297A1 (es) 2023-03-15
JP2023552583A (ja) 2023-12-18
US20240051935A1 (en) 2024-02-15
LT4259617T (lt) 2024-12-10
EP4259617B1 (en) 2024-10-23
EP4259617A1 (en) 2023-10-18
RS66294B1 (sr) 2025-01-31
WO2022122914A1 (en) 2022-06-16
HRP20241543T1 (hr) 2025-01-03
CA3204495A1 (en) 2022-06-16
DOP2023000115A (es) 2023-07-16

Similar Documents

Publication Publication Date Title
US12195448B2 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259617B1 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259616B1 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259618A1 (en) Substituted pyrazolyl piperidine carboxylic acids
EA047635B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
HK40073287A (en) Substituted pyrazolo piperidine carboxylic acids
EA049460B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
BR122025013946A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seus processos de preparação
BR122025013926A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seu processo de preparação e medicamento
HK40118186A (zh) 取代的吡唑并哌啶羧酸
HK40118187A (zh) 取代的吡唑并哌啶羧酸
HK40091213A (zh) 取代的吡唑并哌啶羧酸
HK40073287B (zh) 取代的吡唑并哌啶羧酸

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241121

Comment text: Request for Examination of Application